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HUBUNGAN ANTARA PEMBERIAN STAVUDINE DENGAN 
LIPODISTROFI DAN DISLIPIDEMIA PADA PENDERITA INFEKSI HIV 
DI RSUP DR. KARIADI SEMARANG 
ABSTRAK 
Jacob Bunyamin1, Muchlis A.U. Sofro2 
 
Latar belakang: Pemberian stavudin (d4T) berkontribusi terhadap penurunan 
angka kematian pada penderita HIV. Di lain pihak, stavudin diketahui 
menimbulkan efek samping yang serius seperti lipodistrofi dan dislipidemia. 
Kedua efek samping tersebut dapat meningkatkan resiko terjadinya komplikasi 
pada jantung dan pembuluh darah.     
Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan antara pemberian 
stavudin dengan lipodistrofi dan dislipidemia pada penderita HIV di RSUP Dr. 
Kariadi dan juga mengetahui faktor-faktor yang berhubungan dengan lipodistrofi 
dan dislipidemia. 
Metode: Penelitian ini adalah penelitian observasional analitik dengan metode 
belah lintang. Empat puluh sampel dibagi menjadi kelompok stavudin (23 sampel) 
dan kelompok kontrol (17). Seluruh responden diperiksa profil lipid dan 
lipodistrofi oleh dokter jaga di klinik VCT RSUP Dr. Kariadi. Data yang 
diperoleh dianalisis menggunakan uji Chi-Square dan uji Fisher. 
Hasil: Prevalensi lipodistrofi sebesar 21,7% dan dislipidemia 82,6% pada 
kelompok stavudin. Pemberian stavudin berhubungan signifikan dengan 
dislipidemia (p=0.008) terutama pada kenaikan trigliserida dan penurunan 
kolesterol HDL (p=0.048 dan p=0.009). Pemberian stavudin tidak berhubungan 
signifikan dengan lipodistrofi (p=0.051) walaupun stavudin berhubungan dengan 
lipoatrofi pada pantat dan wajah (p=0.026 dan p=0.013). Jenis kelamin perempuan 
berhubungan dengan lipodistrofi pada kelompok stavudin (p=0.014). Jenis 
kelamin, umur, hitung CD4 dan durasi terapi tidak berhubungan dengan 
dislipidemia pada kelompok stavudin. 
Kesimpulan: Pemberian stavudin berhubungan dengan dislipidemia pada 
penderita HIV di RSUP Dr. Kariadi dan tidak berhubungan dengan lipodistrofi. 
Kata kunci: stavudin, lipodistrofi, dislipidemia, HIV 
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ASSOCIATION BETWEEN STAVUDINE ADMINISTRATION WITH 
LIPODYSTROPHY AND DYSLIPIDEMIA AMONG HIV-INFECTED 
PATIENTS IN DR. KARIADI HOSPITAL SEMARANG 
ABSTRACT 
Jacob Bunyamin1, Muchlis A.U. Sofro2 
 
Background: Stavudine (d4T) administration has contributed in decreasing 
mortality rate of HIV-infected patients. In the other hand, stavudine is known to 
cause serious side effects such as lipodystrophy and dyslipidemia. Both side 
effects are known to increase the risk of developing cardiovascular complications. 
Aims: This study aimed to determine the association between stavudine 
administration with lipodystrophy and dyslipidemia among HIV-infected patients 
in Dr. Kariadi Hospital and also determine the factors associated with 
lipodystrophy and dyslipidemia. 
Methods: This study was an observational analytic study using cross-sectional 
method. Forty samples were divided into stavudine group (23 samples) and 
control group (17). All respondents had their lipid profile observed and 
lipodystrophy assessed by attending physicians in VCT clinic Dr. Kariadi 
Hospital. Obtained data were analyzed using Chi-Square Test and Fisher’s Exact 
Test.  
Results: The prevalence of lipodystrophy was 21.7% and dyslipidemia was 82.6% 
in stavudine group. Stavudine administration was significantly associated with 
dyslipidemia (p=0.008) especially in triglycerides elevation and HDL-c depletion 
(p=0.048 and p=0.009). Stavudine administration was not significantly 
associated with lipodystrophy (p=0.051) although it was associated with 
lipoatrophy of buttock and face (p=0.026 and p=0.013). Being female was 
associated with lipodystrophy incidence in stavudine group (p =0.014). Sex, age, 
CD4 count, and duration of treatment were not associated with dyslipidemia in 
stavudine group.    
Conclusion: Stavudine administration was associated with dyslipidemia among 
HIV-infected patients in Dr. Kariadi Hospital and was not associated with 
lipodystrophy.   
Keywords: stavudine, lipodystrophy, dyslipidemia, HIV 
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Background 
The development of anti retroviral therapy (ART) has reduced mortality 
among HIV/AIDS patients. Coincident with these advances, was described a 
lipodystrophy syndrome occurring in patients taking ART. The syndrome is 
characterized by body fat redistribution and metabolic abnormalities. The 
metabolic disturbances reported are elevated triglyceride, cholesterol and fasting 
blood glucose level. A study taken in Uganda showed that prolonged exposure to 
ART in children contributes to metabolic changes thus increasing the 
cardiovascular risk of adulthood. It is proven that there is a direct connection 
between plasma cholesterol level and the arteriosclerotic process, especially the 
correlation between aortic fatty streaks in young persons with elevated serum 
cholesterol level.1-3    
Stavudine, a Nucleoside Reverse Transcriptase Inhibitor (NRTI), has the 
highest propensity for causing mitochondrial dysfunction, yet it is relatively 
inexpensive and often has better availability in the developing world. According 
to 2013 WHO Antiretroviral Guidelines, stavudine administration should be 
discontinued due to its metabolic toxicities on mitochondria. A drug like 
stavudine has high capacity of inhibiting mtDNA γ-polymerase, which will cause 
mtDNA depletion and lipodystrophy as a further effect. A study in Western India 
showed that the prevalence of lipodystrophy was 46.1% and lipoatrophy was 
significantly associated with stavudine administration. A study in Tanzania 
resulted that 73% patients taking antiretroviral therapy suffered from dyslipidemia 
which was worse in patients who took stavudine.4-8 
In Dr. Kariadi Hospital Semarang, there is little data known about the 
association between stavudine administration to lipodystrophy and dyslipidemia 
in Dr. Kariadi Hospital Semarang. The aim of this study is to determine the 
association between stavudine administration with lipodystrophy and 
dyslipidemia among HIV infected patients in Dr. Kariadi Hospital Semarang and 
also their associated routine demographic informations.  
 
Methods 
This study was an observational analytic study using cross-sectional 
method. This study was conducted on March-May 2014. A preliminary survey 
was conducted on November 2013 – February 2014. The study took place in the 
Voluntary Counseling and Testing (VCT) Clinic of Dr. Kariadi Hospital 
Semarang. Samples were 40 HIV-infected patients administered with stavudine 
containing regimens in Dr. Kariadi Hospital for stavudine group (23 patients) and 
HIV-infected patients administered with zidovudine, lamivudine, and nevirapine 
for control group (17 patients).  
The diagnosis of lipodystrophy was taken from Lipodystrophy Severity 
Grading Score (LSGS) sheet by attending physician in VCT clinic. Routine 
demographic informations such as age, sex, CD4 count, and duration of therapy 
were taken from case record forms. Patients were asked to fast overnight for 9 
hours for lipid profile test. Lipid profiles checked were TG, TC, HDL-c, and 
LDL-c blood level. A 5 ml blood sample was drawn from the patient’s median 
cubital vein. The blood samples were analyzed using automated analyzer in 
Central Laboratory Dr. Kariadi Hospital Semarang. 
Chi-square test was used to determine the association between age, sex, 
current CD4 count, and duration of therapy with the incidence of lipodystrophy 
and dyslipidemia. Ineligible data for chi-square test was analyzed using Fischer’s 
Exact Test. All of data collections and research was under permission of the 
Commission of Health Research Bioethics Faculty of Medicine Diponegoro 
University/Dr. Kariadi Hospital Semarang Indonesia. 
 
Results and Discussions 
Table 1. Samples Characteristics 
Characteristics Stavudine 
Group 
n (%) 
Control 
Group 
n (%) 
P Value 
Lipodystrophy 
P Value 
Dyslipidemia 
Sex 
Male 
Female 
 
12 (52.2) 
11 (47.8) 
 
9 (52.9) 
8 (47.1) 
0.014 0.671 
Age (years) 
Mean 
Range 
 
35.5 
24 – 58 
 
33.8 
22 – 50 
0.545 0.329 
Duration of 
treatment 
(months) 
Mean 
Range 
 
 
30.7 
9 – 121 
 
 
30.8 
6 – 72 
0.673 0.517 
CD4 Count 
(cell/mm3) 
Mean 
Range 
 
234.6 
4 – 597 
 
264.2 
96 – 
512 
0.128 0.614 
ART regimens 
d4T+3TC+ NVP 
d4T+3TC+EVF 
d4T+3TC+TDF 
ZDV+3TC+NVP 
 
6 (26.1) 
15 (65.2) 
2 (8.7) 
- 
 
- 
- 
- 
17 
(100) 
  
 
There were 21.7% patients with lipodystrophy in stavudine group. None of 
the patients in the control group acquired lipodystrophy. The prevalence is lower 
compared to a study in India, which was 46.1% for lipodystrophy.Another study 
in Australia reported that lipodystrophy in HIV-infected patients’ prevalence 
reached 53%, in which 55% reported both peripheral lipoatrophy and central 
lipohypertrophy, 31% with peripheral lipoatrophy only and 14% had central 
lipohypertrophy only. In Ethiopia, the prevalence was 68.3%.7,9-10 
 Dyslipidemia accounted in 82.6% of patients in stavudine group. This 
percentage is twice higher from the control group which was 41.2%. The 
percentage of normal lipid profile in stavudine group was 17.4% while the control 
group’s was 58.8%. A study in Uganda showed that the prevalence of stavudine-
associated dyslipidemia was 91%. A research in Kenya resulted that the 
prevalence of dyslipidemia was 63.1% in patients administered with stavudine.11-
12 
 
Table 2. Association between Stavudine and Lipodystrophy 
 
Variables 
Stavudine Group Control Group  
P Value n (%) n (%) 
Lipodystrophy 
Absent 
Total 
5 (21.7) 
18 (78.3) 
23 (100.0) 
0 (0.0) 
17 (100.0) 
17 (100.0) 
0.051 
 
 
Table 3. Fat Distribution Changes Overview 
 
Variables 
Stavudine group Control group  
P value Fat 
distribution 
changes 
Absent Fat 
distribution 
changes 
Absent 
n (%) n (%) n (%) n (%) 
Lipoatrophy 
Upper arm 
Thigh 
Buttock 
Face 
 
4 (17.4) 
5 (21.7) 
6 (26.1) 
7 (30.4) 
 
19 (82.6) 
18 (78.3) 
17 (73.9) 
16 (69.6) 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
17 (100) 
17 (100) 
17 (100) 
17 (100) 
 
0.097 
0.051 
0.026 
0.013 
Lipohypertrophy 
Abdomen 
Breasts 
Nuchae 
Chin 
 
8 (34.8) 
3 (13.0) 
4 (17.4) 
1 (4.3) 
 
15 (65.2) 
20 (87.0) 
19 (82.6) 
22 (95.7) 
 
6 (35.3) 
2 (11.8) 
0 (0.0) 
0 (0.0) 
 
11 (64.7) 
15 (88.2) 
17 (100) 
17 (100) 
 
0.616 
0.646 
0.097 
0.575 
 
The statistical analysis showed that the administration of stavudine did not 
significantly correlate to lipodystrophy incidences in HIV-infected patients. A 
study in Rwanda found that stavudine administration had significant correlation 
with lipodystrophy (p=0.019). Van Griensven et al. showed that stavudine had 
significant association with facial lipodystrophy (p=0.011), thigh atrophy 
(p=0.006), and buttock atrophy (p=0.009) compared to zidovudine.1,13 
These differences were likely caused by the lack of lipodystrophy 
definition in clinical settings. This study used Lipodystrophy Severity Grading 
Score (LSGS) measured by physical examination by attending physician while 
another study were conducted using data from patients’ self reports or DEXA 
although Carter et al. stated that the results of both methods werely balanced. A 
study concluded that the prevalence of lipodystrophy would be different because 
of different definitions of lipodystrophy applied which may result in different 
statistical significance. The sample size of this study was also considered less 
compared to various studies in other countries. 14 
Sex was the only factor that significantly correlated with lipodystrophy in 
stavudine group (p=0.014). This finding was consistent with several studies 
conducted in Rwanda and South Africa which stated that being female was a 
significant risk factor in developing lipodystrophy. Females were also reported to 
have more central lipohypertrophy (p<0.0001), a pattern of lipodystrophy found 
most frequently in this study.Females were known to have impaired lipid profile 
due to the lack of 17-beta estradiol after menopause which increased LDL-c and 
decreased HDL-c levels, although the median age of this study was 35.5 years 
old.10,13,15 
Meanwhile, age, duration of treatment and CD4 count did not have 
significant correlation with lipodystrophy in HIV-infected patients in Dr. Kariadi 
Hospital (p=0.545, p=0.128 and p=0.673).These findings were different with a 
study in Rwanda which stated that duration of treatment ≥ 18 months and CD4 
count ≥150 cell/mm3 had significant correlation with lipodystrophy (p=0.020 and 
p=0.014) while age was not significantly correlated (p=0.328). These differences 
may be caused by different sample size and different methods of diagnosing 
lipodystrophy.13,16 
Although lipodystrophy is seen as cosmetic problem, the presence of 
lipodystrophy may suggest metabolical disturbance such as dyslipidemia, 
impaired glucose level, or hyperlactatemia. Clinically diagnosed lipodystrophy 
may become useful hints in detecting metabolic abnormalities in a resources 
limited setting. The presence of lipodystrophy may also cause stigma in HIV-
infected patients and discrimination. Hadigan et al. found that among HIV-
infected patients with lipoatrophy, the LDL-c particle exhibited a proatherogenic 
pattern.17 
 
 
Table 4. Association between Stavudine and Dyslipidemia 
 
Variables 
Stavudine Group Control Group  
P Value n (%) n (%) 
Dyslipidemia 
Normal 
Total 
19 (82.6) 
4 (17.4) 
23 (100.0) 
7 (41.2) 
10 (58.8) 
17 (100.0) 
0.008 
 
Table 5. Lipid Profile Changes Overview 
 
Variables 
Stavudine group Control group  
P 
Value 
Increased Normal Increased Normal 
n (%) n (%) n (%) n (%) 
TC (mg/dL) 
 
10 (43.5) 13 (56.5) 4 (23.5) 13 (76.5) 0.166 
TG (mg/dL) 11 (47.8) 12 (52.2) 3 (17.6) 14 (82.4) 0.048 
HDL(mg/dL)1 12 (52.2) 11 (47.8) 2 (11.8) 15 (88.2) 0.009 
LDL (mg/dL) 8 (34.8) 15 (65.2) 2 (11.8) 15 (88.2) 0.096 
1 : Decreased HDL 
Stavudine administration was significantly associated with dyslipidemia 
among HIV-infected patients in Dr. Kariadi Hospital. This result was consistent 
with a study taken in Uganda which also compared stavudine with zidovudine 
(p=0.001).11 
Stavudine was significantly associated with elevated TG level and 
decreased HDL-c level. Administration of stavudine was not significantly 
correlated with both TC and LDL-c increases. This finding corresponded with the 
fact that dyslipidemia in HIV-infected patients is mostly characterized by 
hypertriglyceridemia and low HDL-c concentrations. Stavudine was also 
associated with higher TG elevation (p<0.05).18-19 
This study found that sex, age, CD4 count, and duration of therapy had no 
significant association with dyslipidemia in stavudine group. This finding was 
similar with a study in Uganda which stated that sex, age, CD4 count, and 
duration of treatment had no significant association with dyslipidemia.11 
Although being male and age ≥ 35 were considered as traditional risk 
factors of dyslipidemia, this finding was not seen in HIV-infected patients treated 
with stavudine in Dr. Kariadi Hospital. Confounding factors such as unhealthy 
diet, tobacco smoking and sedentary lifestyle may have role in impaired lipid 
profiles since most patients reported to do sport less than three times in a week 
and several patients claimed to have smoking history. 
Peak body weight > 65 kg, family history of diabetes mellitus, family 
history of hypertension, and lipodystrophy were determined as risk factors for 
dyslipidemia in HIV-infected patients in Uganda. This study excluded patients 
with history of metabolic syndrome due to already impaired lipid profiles prior to 
stavudine administration.11 
Elevated TG level is known as a risk factor of atherosclerosis which leads 
to heart attack and stroke. This impaired lipid profile may also cause pancreatic 
inflammation. The level HDL-c is a more potent risk factor for coronary heart 
disease compared to LDL-c level in blood. A study found that the risk of 
developing coronary heart disease decreases 2-3% for every 1 mg/dL increase of 
HDL-c. Pharmacological intervention and lifestyle modification should be 
promoted to patients with impaired lipid profiles. A reduction in dietary 
carbohydrate intake may improve an atherogenic lipid profile. 20 
It is recommended to switch stavudine with safer NRTI such as 
zidovudine (AZT) in limited resources area. Abacavir (ABC) and tenofovir (TDF) 
may be used if the situation is possible. Studies showed that either abacavir or 
tenofovir administration may improve increased lipid profiles caused by stavudine 
although abacavir did not reverse lipodystrophy effectively.21-22 
Several limitations of this study were the sample size was not large 
compared to other studies conducted in different countries. We also could not 
determine the association between Body Mass Index (BMI) with lipodystrophy 
and dyslipidemia because the lack of data needed to assess BMI of HIV-infected 
patients in Dr. Kariadi Hospital Semarang.  
Conclusions 
Stavudine administration was significantly associated with dyslipidemia 
among HIV-infected patients in Dr. Kariadi Hospital and was not associated with 
lipodystrophy. Sex was siginificantly associated with lipodystrophy in stavudine 
group while age, CD4 count, and duration of treatment were not. None of the 
routine demographic informations were significantly associated with dyslipidemia 
in stavudine group. 
Suggestions 
Stavudine should be phased out as first-line drugs in HIV treatment in Dr. 
Kariadi Hospital Semarang due to its metabolic side effects such as dyslipidemia 
and lipodystrophy. Zidovudine, abacavir or tenofovir should be used to replace 
stavudine due to its ability to improve disturbed lipid profiles in patients with 
stavudine associated dyslipidemia.  
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